Stabilizing Mandibular Overdentures with a Single Implant Placed in the Canine Region of the Preferred Chewing Side (c-SIMO)

March 25, 2025 updated by: Frauke Müller

Stabilizing Mandibular Overdentures with a Single Implant Placed in the Canine Region of the Preferred Chewing Side Compared to the Midline Single-implant Overdenture Treatment Concept: an RCT with 5 Years of Follow-up

The investigators are evaluating the use of a single implant to stabilize complete dentures in the lower jaw, in the canine region of the preferred chewing side. They are conducting this study to determine whether this treatment concept gives satisfactory results, and how it compares with the standard position in the center of the lower jaw.

Study Overview

Status

Recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Geneva, Switzerland, 1211
        • Recruiting
        • University Clinics of Dental Medicine, University of Geneva
        • Contact:
        • Contact:
          • Sabrina Maniewicz

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Informed consent signed by the subject
  • Age ≥ 60 years
  • Edentulous and wearing sufficient complete maxillary and mandibular dentures or ones that can be rendered sufficient via a reline and/or renewal of the prosthetic teeth
  • Healed edentulous mandible (minimum 6-8 weeks since last extraction in the anterior zone (4-4) and one year in the posterior zone (5-8))
  • Physical status ASA1 and ASA2

Exclusion Criteria:

  • Contraindications to the medical devices used, e.g. known hypersensitivity or allergy
  • Vulnerable subjects
  • Enrollment of the investigator, his/her family members, employees and other dependent persons
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to perform adequate oral hygiene
  • Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, Parkinson etc. of the subject (Dementia: clock-drawing test score ≤ 5)
  • Surgical risk factors such as, but not limited to, uncontrolled diabetes, immunosuppression, radiation, chemotherapy, or antiresorptive medication (ex. Bisphosphonates)
  • Heavy smoking habit: >20 cig/d
  • Reported severe bruxism or clenching habits, clinically present oro-facial pain
  • Depression: Geriatric Depression Scale > 9
  • Xerostomia: SSFR ≤ 0.7ml/min
  • Ridge dimensions <6 mm (width) by 10 mm (height) in the canine or midline area
  • Ridge defects requiring bone augmentation procedures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: c-SIMO
Placement of an implant in the mandibular canine area and using it to stabilize a pre-existing mandibular complete denture.
Placement of an implant in the mandibular canine area and using it to stabilize a pre-existing mandibular complete denture.
Active Comparator: m-SIMO
Placement of an implant in the midline of the mandible and using it to stabilize a pre-existing mandibular complete denture.
Placement of an implant in the midline of the mandible and using it to stabilize a pre-existing mandibular complete denture.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
OHIP-EDENT
Time Frame: From baseline to 5-year follow-up
Oral health-related quality of life questionnaire
From baseline to 5-year follow-up
DSI
Time Frame: From baseline to 5-year follow-up
Denture Satisfaction Index (questionnaire)
From baseline to 5-year follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Preferred chewing side
Time Frame: From baseline to 5-year follow-up
Asymmetry Index
From baseline to 5-year follow-up
Chewing efficiency
Time Frame: From baseline to 5-year follow-up
two-color mixing ability test
From baseline to 5-year follow-up
Occlusal analysis
Time Frame: From baseline to 5-year follow-up
Dental Prescale System
From baseline to 5-year follow-up
Plaque index
Time Frame: From implant loading to 5-year follow-up
modified Plaque Index (modPI)
From implant loading to 5-year follow-up
Bleeding on probing
Time Frame: From implant loading to 5-year follow-up
modified Bleeding Index (modBI)
From implant loading to 5-year follow-up
Pocket probing depth
Time Frame: From implant loading to 5-year follow-up
Peri-implant probing depth
From implant loading to 5-year follow-up
Keratinized peri-implant tissues
Time Frame: From implant loading to 5-year follow-up
Measurement of the keratinized tissue around implants
From implant loading to 5-year follow-up
Prosthodontic assessment
Time Frame: From implant loading to 5-year follow-up
Number of prosthetic complications
From implant loading to 5-year follow-up
Peri-implant bone height
Time Frame: From implant loading to 5-year follow-up
Measured on radiographs
From implant loading to 5-year follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Sabrina Maniewicz, University of Geneva
  • Study Director: Frauke Müller, University of Geneva

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2025

Primary Completion (Estimated)

December 1, 2031

Study Completion (Estimated)

December 1, 2031

Study Registration Dates

First Submitted

December 15, 2024

First Submitted That Met QC Criteria

December 23, 2024

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Estimated)

March 26, 2025

Last Update Submitted That Met QC Criteria

March 25, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • DGPA_2024_02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Completely Edentulous Patients

Clinical Trials on c-SIMO

Subscribe